XAIR
Beyond Air, Inc. Common Stock
stockNASDAQ
Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System, LungFit™, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs of ventilated and non-ventilated patients for the potential treatment of a variety of pulmonary diseases. LungFit™ can generate up to 400 ppm of NO for delivery either continuously or for a fixed amount of time, and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its innovative LungFit™ in clinical trials for the treatment of severe lung infections such as SARS-CoV-2 and nontuberculous mycobacteria (NTM). Additionally, Beyond Air is performing preclinical testing of the use of ultra-high concentrations of NO with a proprietary delivery system, separate from LungFit™, to target certain solid tumors.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 2.25 | 2026-10-09 | -4.00% | 4.058 |
| 1M | 3.08 | 2026-09-17 | -29.87% | 1.203 |
| 3M | 5.58 | 2026-07-17 | -61.29% | 2.696 |
| 6M | 10.88 | 2026-04-17 | -80.15% | 0.732 |
| 1Y | 47.20 | 2025-10-17 | -95.42% | 0.522 |
| 2Y | 138.00 | 2024-10-17 | -98.44% | — |
| 5Y | 4,252.00 | 2021-10-18 | -99.95% | 0.949 |
Beyond Air, Inc. Common Stock (NASDAQ:XAIR) stock price today is $2.16, and today's volume is 14,691. XAIR is down 2.262% today. The 30 day average volume is 73,523. XAIR market cap is $2.13M with 984,407 shares outstanding.